Who are Trifluridine-tipiracil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fluoro-L-thymidine-(18F), Biktarvy, Pifeltro, BICTEGRAVIR SODIUM, TENOFOVIR ALAFENAMIDE FUMARATE, Lonsurf.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trifluridine-tipiracil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Trifluridine-tipiracil — Competitive Intelligence Brief

Trifluridine-tipiracil (Trifluridine-tipiracil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog. Area: Oncology.

phase 3 Nucleoside analog Thymidine kinase 1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Trifluridine-tipiracil (Trifluridine-tipiracil) — The Methodist Hospital Research Institute. Trifluridine-tipiracil is a thymidine kinase 1 inhibitor that also has a thymidylate synthase inhibitor component, which works by interfering with DNA synthesis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trifluridine-tipiracil TARGET	Trifluridine-tipiracil	The Methodist Hospital Research Institute	phase 3	Nucleoside analog	Thymidine kinase 1
Fluoro-L-thymidine-(18F)	Fluoro-L-thymidine-(18F)	Assistance Publique - Hôpitaux de Paris	phase 3	PET imaging agent / radiopharmaceutical	Thymidine kinase 1 (TK1)
Biktarvy	BICTEGRAVIR	Gilead Sciences	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01
Pifeltro	DORAVIRINE	Merck & Co.	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01
BICTEGRAVIR SODIUM	BICTEGRAVIR SODIUM		marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01
TENOFOVIR ALAFENAMIDE FUMARATE	TENOFOVIR ALAFENAMIDE FUMARATE		marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2015-01-01
Lonsurf	TIPIRACIL	Taiho Oncology Inc	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-09-22 — Lonsurf · RE46284 · US
2032-08-15 — Biktarvy · 8754065 · US
2032-08-15 — Biktarvy · 9296769 · US
2033-02-15 — Biktarvy · 8754065*PED · US
2033-02-15 — Biktarvy · 9296769*PED · US
2033-12-19 — Biktarvy · 9216996 · US
2033-12-19 — Biktarvy · 9732092 · US
2034-06-17 — Lonsurf · 10457666 · US
2034-06-17 — Lonsurf · 9527833 · US
2034-09-05 — Lonsurf · 9943537 · US
2035-06-19 — Biktarvy · 9708342 · US
2035-06-19 — Biktarvy · 10385067 · US
2036-11-08 — Biktarvy · 10548846 · US
2037-02-03 — Lonsurf · 10960004 · US
2037-02-03 — Lonsurf · 10456399 · US

Sponsor landscape (Nucleoside analog class)

Third Affiliated Hospital, Sun Yat-Sen University · 2 drugs in this class
Actuate Therapeutics Inc. · 2 drugs in this class
City of Hope Medical Center · 1 drug in this class
Cooperative Study Group A for Hematology · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Innovent Biologics (Suzhou) Co. Ltd. · 1 drug in this class
Osaka Medical Center for Cancer and Cardiovascular Diseases · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class
The Methodist Hospital Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trifluridine-tipiracil — Competitive Intelligence Brief. https://druglandscape.com/ci/trifluridine-tipiracil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab